The Number That Judges an Embryo: AI Genetic Scoring in IVF Demands Ethical Reckoning
A number appears on a screen. It does not represent a grade, a credit score, or a stock price. It represents the aggregate genetic risk of a future human being—computed, according to its creators, from variations in an embryo's DNA with the help of artificial intelligence. The number is called the polygenic risk score. And it is quietly reshaping how prospective parents in several countries think about the IVF process.
Polygenic risk scores represent a fundamental shift in preimplantation genetic screening. Traditional IVF selection focused on identifying single-gene disorders—conditions caused by one malfunctioning gene, such as cystic fibrosis or Huntington's disease. PRS attempts something considerably broader: it aggregates thousands of genetic variants, each contributing a tiny effect, to estimate an embryo's probabilistic risk for conditions ranging from type 2 diabetes to schizophrenia to certain cancers. The ambition is to rank embryos on a single continuum of projected lifetime health burden and select accordingly.
The scientific case for this ambition is substantially weaker than the marketing suggests. Polygenic associations are population-specific, derived overwhelmingly from cohorts of European ancestry, and they explain only a fraction of the heritability of the conditions they purport to predict. A 2023 analysis in Nature Genetics noted that PRS portability across ancestries remains "an unsolved challenge," with risk predictions degrading sharply for individuals of non-European descent. That limitation matters enormously in a global market for reproductive services. It means a score that appears precise in one population may be largely meaningless in another—a statistical artefact masquerading as biological signal.
The regulatory architecture has not kept pace. In the United States, the Food and Drug Administration has signalled interest in supervising laboratory-developed tests, but no comprehensive framework specifically governing PRS in the IVF context has been enacted. In the United Kingdom, the Human Fertilisation and Embryology Authority oversees fertility clinics but has not issued definitive guidance on polygenic screening. The European Union's In Vitro Diagnostic Medical Devices Regulation offers some scaffolding, but application to embryo selection tools remains ambiguous. Clinics operating in this space are, in effect, deploying a health intervention without an agreed regulatory definition of what it is or what evidence it must produce.
The commercial dimension compounds the concern. Fertility medicine is a growth industry, and the addition of algorithmic ranking to the IVF pipeline creates a premium service tier. Patients paying for PRS are not simply choosing to avoid a known genetic disorder—they are purchasing a probabilistic forecast about diseases they may never develop, in a body that does not yet exist. The framing normalises selection for health traits that are themselves the product of complex gene-environment interactions, creating market incentives to inflate the perceived utility of scores whose predictive value remains genuinely contested.
There is a further dimension that the industry rarely discusses in marketing materials: the disability rights critique. The assumption that lower genetic risk equals a life more worth living is not neutral. It carries, often implicitly, the idea that people born with conditions like autism or deafness or dwarfism are outcomes to be prevented rather than persons to be accommodated. That framing has deep roots in eugenics history, and its recurrence in a commercial reproductive context—dressed in the language of choice and personalisation—warrants scrutiny that goes beyond individual clinic ethics committees.
What distinguishes this moment from earlier controversies in reproductive medicine is the algorithmic layer. PRS does not simply report a binary fact about a specific mutation. It generates a continuous score, ranks embryos relative to one another, and presents the result as an objective computation. That framing makes the selection decision feel like reading data rather than making a value judgment. It is not. The ranking of embryos by probabilistic future health is a profound ethical act, and the automation of that act does not eliminate the ethical weight—it obscures it.
The path forward requires, at minimum, three things: transparency about what PRS can and cannot predict, including honest disclosure of population-specific limitations; regulatory clarity on the status of polygenic screening as a medical device or a laboratory service; and a genuine public conversation—not one mediated by fertility clinic marketing—about whether, and under what conditions, probabilistic selection of embryos is appropriate. That conversation is not happening at the speed the technology is moving.
This publication has previously covered commercial genomic testing in direct-to-consumer contexts; the PRS-in-IVF extension represents a qualitatively different application, moving from information provision to active selection guidance, which is why a separate ethical reckoning is warranted now.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://t.me/theprintindia/31942
- https://t.me/theprintindia/31939